U.K.'s Cost Effectiveness Watchdog Backs Novo Nordisk's Victoza
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE recommends Novo Nordisk's diabetes therapy Victoza, but only at one dose and as an alternative to other therapies.
You may also be interested in...
NICE Likely To Lose Cost-Watchdog Status By 2013
The U.K.'s National Institute for Clinical Excellence (NICE) will likely no longer have any role in drug cost-effectiveness decisions after 2013, according to officials.
NICE Likely To Lose Cost-Watchdog Status By 2013
The U.K.'s National Institute for Clinical Excellence (NICE) will likely no longer have any role in drug cost-effectiveness decisions after 2013, according to officials.
NICE Likely To Lose Cost-Watchdog Status By 2013
A new value-based pricing system will make NICE's cost-assessment role redundant, say U.K. ministers.